Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average of $0.91

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.91 and traded as low as $0.61. Seres Therapeutics shares last traded at $0.62, with a volume of 3,849,237 shares trading hands.

Analyst Ratings Changes

MCRB has been the topic of a number of analyst reports. Oppenheimer cut their price target on shares of Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 6th. Chardan Capital cut their price target on shares of Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 6th.

Seres Therapeutics Stock Performance

The stock has a market capitalization of $93.31 million, a price-to-earnings ratio of -0.69 and a beta of 2.24. The firm’s fifty day simple moving average is $0.91 and its 200 day simple moving average is $1.17.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.50 million. Analysts forecast that Seres Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

Hedge funds have recently bought and sold shares of the stock. Simplicity Solutions LLC acquired a new stake in Seres Therapeutics during the 3rd quarter worth approximately $27,000. Hudson Bay Capital Management LP grew its stake in shares of Seres Therapeutics by 127.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after acquiring an additional 1,119,800 shares in the last quarter. Aigen Investment Management LP grew its stake in shares of Seres Therapeutics by 577.1% during the 3rd quarter. Aigen Investment Management LP now owns 75,241 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 64,128 shares in the last quarter. Graham Capital Management L.P. grew its stake in shares of Seres Therapeutics by 731.3% during the 3rd quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock worth $492,000 after acquiring an additional 181,957 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Seres Therapeutics during the 3rd quarter worth approximately $120,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.